伴随着国产GLP-1减重药玛仕度肽(商品名:信尔美)的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和

智通财经
06 Jul
伴随着国产GLP-1减重药玛仕度肽(商品名:信尔美)的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和诺德与礼来在中国市场将面临更激烈的竞争环境减重药未来价格是否会出现松动也引发关注。 7月3日信达生物的GLP-1减重创新药玛仕度肽“首方”落地。北京大学人民医院分泌科主任医师纪立农教授为一名超重合并脂肪肝的患者开出全国首张处方标志着玛仕度肽正式进入国内公立医院。这距离该药物获批仅一周之隔。下周起该药物将陆续进入全国各大公立医院。 相比之下诺和诺德的司美格鲁肽减重适应症(商品名:诺和盈)从获批到正式商业化开出公立医院“首方”历时近5个月;礼来的替尔泊肽减重适应症从获批到上市也经历了近半年时间。 “国内厂商没有产能供应限制的问题。”一位业内人士对第一财经记者。另据记者了解直到目前为止司美格鲁肽与替尔泊肽均尚未在国内实现本土化生产。(第一财经)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10